AU2002246827B2 - Methods for modulating tumor growth and metastasis - Google Patents

Methods for modulating tumor growth and metastasis Download PDF

Info

Publication number
AU2002246827B2
AU2002246827B2 AU2002246827A AU2002246827A AU2002246827B2 AU 2002246827 B2 AU2002246827 B2 AU 2002246827B2 AU 2002246827 A AU2002246827 A AU 2002246827A AU 2002246827 A AU2002246827 A AU 2002246827A AU 2002246827 B2 AU2002246827 B2 AU 2002246827B2
Authority
AU
Australia
Prior art keywords
combretastatin
compound
tumor
administration
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002246827A
Other languages
English (en)
Other versions
AU2002246827A1 (en
Inventor
David Chaplin
Klaus Edvardsen
Francis Y. Lee
Ronald Peck
Ronald Pero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Mateon Therapeutics Inc
Original Assignee
Bristol Myers Squibb Co
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Oxi Gene Inc filed Critical Bristol Myers Squibb Co
Publication of AU2002246827A1 publication Critical patent/AU2002246827A1/en
Application granted granted Critical
Publication of AU2002246827B2 publication Critical patent/AU2002246827B2/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY, MATEON THERAPEUTICS, INC. reassignment BRISTOL-MYERS SQUIBB COMPANY Request to Amend Deed and Register Assignors: BRISTOL-MYERS SQUIBB COMPANY, OXIGENE, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2002246827A 2000-12-22 2001-12-20 Methods for modulating tumor growth and metastasis Ceased AU2002246827B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25819500P 2000-12-22 2000-12-22
US60/258,195 2000-12-22
PCT/US2001/050261 WO2002056692A1 (en) 2000-12-22 2001-12-20 Methods for modulating tumor growth and metastasis

Publications (2)

Publication Number Publication Date
AU2002246827A1 AU2002246827A1 (en) 2003-02-13
AU2002246827B2 true AU2002246827B2 (en) 2008-02-21

Family

ID=22979500

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002246827A Ceased AU2002246827B2 (en) 2000-12-22 2001-12-20 Methods for modulating tumor growth and metastasis

Country Status (5)

Country Link
EP (1) EP1351573A4 (enExample)
JP (2) JP2004523517A (enExample)
AU (1) AU2002246827B2 (enExample)
CA (1) CA2432792C (enExample)
WO (1) WO2002056692A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326761C (en) 1998-04-03 2008-02-19 Ajinomoto Co., Inc. Antitumor agent
IL153218A0 (en) 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
AU2002216029B2 (en) 2000-10-27 2006-01-05 Pfizer, Inc. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
JP2004523517A (ja) * 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
WO2004028474A2 (en) * 2002-09-25 2004-04-08 University Of Rochester Caspase inhibitors as anticancer agents
WO2004032947A1 (en) * 2002-10-09 2004-04-22 Unibioscreen S.A. Extract with anti-tumor and anti-poisonous activity
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2047858A1 (en) * 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
DK2219451T3 (en) * 2007-11-21 2015-01-12 Oxigene Inc A method for the treatment of hematopoietic neoplasms
WO2009103076A1 (en) * 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
CN107773556B (zh) * 2016-08-26 2020-08-18 广州安好医药科技有限公司 一种具有抗肿瘤药物功效的联合用药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JP2002500227A (ja) 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−４プロドラッグとそのトランス異性体
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
JP2002537262A (ja) 1999-02-18 2002-11-05 オキシジェン，インコーポレイティド 血管破壊のターゲッティングに使用するための組成物および方法
JP2004523517A (ja) * 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D1: Grosios K. et al. Anticancer Research 2000 Jan-Feb, 20(1A):229-233 *
D2: Horsman M.R. et al. Advances in Experimental Medicine and Biology 2000: 467:311-323 *

Also Published As

Publication number Publication date
CA2432792A1 (en) 2002-07-25
JP2009102350A (ja) 2009-05-14
WO2002056692A1 (en) 2002-07-25
CA2432792C (en) 2012-04-03
EP1351573A4 (en) 2007-03-28
EP1351573A1 (en) 2003-10-15
JP2004523517A (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
AU2002246827B2 (en) Methods for modulating tumor growth and metastasis
US20090258937A1 (en) Methods for Modulating Tumor Growth and Metastasis
AU2002246827A1 (en) Methods for modulating tumor growth and metastasis
US20090209496A1 (en) Methods and compositions for enhancing the efficacy of rtk inhibitors
EP1173187B1 (en) Combined preparations comprising morpholine anthracyclines and platinum derivatives
PL205728B1 (pl) Kombinacja zawierająca kombretastatynę i czynniki przeciwnowotworowe
US20080214509A1 (en) Methods for enhancing the efficacy of vascular disrupting agents
US20050209310A1 (en) Methods for modulating tumor growth and metastasis
KR101505415B1 (ko) 이소포스포르아미드 머스타드의 염 및 이의 동족체
ZA200202689B (en) Formulations for parenteral use of estramustine phosphate and amino acids.
AU1583201A (en) Combination chemotherapy
JP2006528696A (ja) 抗癌剤の抗腫瘍活性を増強する方法
US6562834B2 (en) Combination comprising camptothecin and a stilbene derivative for the treatment of cancer
AU5063302A (en) Combination chemotherapy
AU2004248968A1 (en) Compositions comprising ZD6126 together with 5-FU, CPT-11 or 5-FU and CPT-11 having vascular damaging activity for treating e.g. colorectal cancer
WO2009129333A1 (en) Methods for enhancing the efficacy of vascular disrupting agents
US20040014729A1 (en) Use of estramustine phosphate in the treatment of bone metastasis
Arita et al. 219 Prediction of carboplatin clearance on Japanese lung cancer patients
Zaniboni et al. 220 Taxol, ifospamide and carboplatin for NSCLC: A phase II study
Sørensen et al. 218 Phase II study of bi-weekly paclitaxel (P) and cisplatin (C) for non-resectable non small-cell lung cancer (NSCLC)
Gatzemeiera et al. Phase II Trial Using Tauromustine in Patients with Extended Non-Small Cell Lung Cancer
US20030134893A1 (en) Combination chemotherapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired